AprilBio Signs Technology Introduction Agreement with Curigin for Dual-Target siRNA Platform Metabolic Disease Therapeutics
AprilBio has entered into a technology introduction agreement with Curigin for dual-target siRNA platform-based metabolic disease drug candidates.
The contract is conditional, with cost recognition dependent on clinical and regulatory success, and carries termination risks.
The contract amount is undisclosed but exceeds 10% of latest annual sales, comprising upfront and milestone payments with revenue sharing in case of sublicensing.
The term extends until the latest of patent expiry, regulatory exclusivity expiration, or 12 years from first commercial sale.
[AI Summary]AprilBio strengthened its R&D pipeline by licensing new technology without capital dilution. Short-term financial impact is limited, but long-term growth potential hinges on clinical success. Uncertainty remains due to undisclosed terms and conditional nature.
KOSDAQ Filing Information
Major Management Matters Related to Investment Decision (Technology Introduction Contract Signed)